Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426874 | 0.83 | SCN9A (0.36) | ALDH1A1GAASCN9ATSHRHSD17B10 | |
| SCHEMBL13306376 | 0.79 | SCN9A (0.45) | ALDH1A1GAASCN9ACES1 | |
| SCHEMBL2429034 | 0.72 | DRD1 (0.39) | ALDH1A1TSHRHSD17B10CES1PKM | |
| SCHEMBL15314987 | 0.69 | TSHR (0.55) | ALDH1A1GAASCN9ATSHRHSD17B10 | |
| SCHEMBL281702 | 0.67 | SCN9A (0.46) | ALDH1A1GAASCN9ATSHRHSD17B10 | |
| SCHEMBL2427072 | 0.67 | SCN9A (0.38) | ALDH1A1GAASCN9ACES1 | |
| SCHEMBL2429837 | 0.67 | SCN9A (0.35) | ALDH1A1GAASCN9A | |
| SCHEMBL27728425 | 0.66 | SCN9A (0.47) | ALDH1A1GAASCN9ATSHRHSD17B10 | |
| SCHEMBL2998882 | 0.65 | SCN9A (0.56) | ALDH1A1SCN9ATSHRHSD17B10 | |
| SCHEMBL1612096 | 0.65 | KMT2A (0.63) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237567-A9 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | ALDH1A1 1829/4885GAA 3870/4885SCN9A 57/4885 |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | ALDH1A1 1829/4885GAA 3870/4885SCN9A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.